The State of Biosimilars: What to Watch
Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can deliver on big health care savings?
‘The Price of Business’: Discussing the Latest Inflation Report
On July 12, Alex Brill joined Kevin Price on ‘The Price of Business’ to discuss the latest inflation report. What could be behind the significant drop?
Alex Brill Interviewed on the Future of the Adalimumab Market
MGA’s Alex Brill was interviewed by Mari Serebvrov for a new piece in BioWorld to discuss the latest with the adalimumab market as new competition is expected as early as July 1.
Taking Stock of the Humira Biosimilars Market
In January, the 21-year monopoly for AbbVie’s blockbuster drug Humira (adalimumab) came to an end with the launch of Amjevita, Amgen’s biosimilar adalimumab.
MGA’s Alex Brill on CNBC’s Squawk Box Discussing House Republican tax proposals
Alex Brill joined CNBC’s Squawk Box to discuss Biden’s billionaire tax policy proposal and why it is not desirable for the U.S. economy.
- Implications of Cannabis Legalization for the US Federal Budget
- Biden Budget Proposes a Step Toward Biologic Drug Competition
- MGA Releases Economic Impact Report for Multinational Pharmaceutical Company
- MGA’s Alex Brill on CNBC’s Squawk Box Discussing Tackling the Tax Gap
- The Next Tax Fight: SALT
- Alex Brill on Single-Payer Health Care System and Drug Costs
- New MGA Analysis Finds Drug Rebates Not Associated with List Price Increases
- The Threat to Preferred Pharmacy Networks
- Alex Brill mentioned on MSN
- Alex Brill Speaks on Consequences of Proposed PBM Constraints
